GlassScriptPhysician profile
Christopher J Anderson
NPI 1669889820
$4,529.38
in general payments reported to CMS, 2019-2025
25 companies · $516 in 2025
The $516 reported for 2025 was more than what 76% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $679 · 2022: $1,147 · 2023: $1,329 · 2024: $858 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,703.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,703.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,414.73 | 2021-2025 | |
| Novo Nordisk INC | $922.95 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Corium, LLC | $404.45 | 2022-2024 | Azstarys |
| Phathom Pharmaceuticals, INC. | $395.84 | 2023-2025 | Voquezna |
| Supernus Pharmaceuticals, INC. | $321.93 | 2022-2024 | Qelbree, Qelbree |
| Astrazeneca Pharmaceuticals LP | $157.66 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $140.16 | 2021-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $120.85 | 2021-2022 | |
| Stryker Corporation | $96.16 | 2025 | Artix Mt, Clottriever Bold Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.24 | 2021-2022 | |
| Lilly USA, LLC | $80.66 | 2022 | |
| Ani Pharmaceuticals, INC. | $76.55 | 2023 | Purified Cortrophin Gel |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.94 | 2022-2023 | |
| Sunovion Pharmaceuticals INC. | $44.68 | 2021 | |
| Almatica Pharma LLC | $27.11 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $25.26 | 2022 | |
| Alk-Abello, INC | $21.49 | 2025 | Neffy |
| Inari Medical, INC. | $21.29 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Alkermes, INC. | $20.84 | 2023 | Vivitrol |
| Vanda Pharmaceuticals INC. | $19.76 | 2025 | Fanapt |
| Astellas Pharma US INC | $19.33 | 2025 | Veozah |
| Organogenesis INC. | $18.58 | 2025 | Puraply Wound Matrix |
| Heron Therapeutics, INC. | $18.07 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.82 | 2022 | |
| Zealand Pharma US, INC. | $15.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.